Curriculum vitae

CURRICULUM VITAE
August 2007

NAME:
DATE OF BIRTH: June 17, 1941
BIRTHPLACE:

PRESENT BUSINESS ADDRESS:
The Center for Diabetes & Endocrine Care 1150 North 35th Avenue Suite 590 Hollywood, Florida 33021 (954)-963-7100

PREVIOUS BUSINESS ADDRESS:
3700 Washington Street Suite 305 Hollywood, Florida 33021 (954)-963-7100
PRE-PROFESSIONAL EDUCATION:
City College of New York Masters Program in Biology New York City, N.Y.

PROFESSIONAL EDUCATION:
1. Wayne State University School of Medicine Detroit, Michigan M.D. 1965-1969 Page 1
Curriculum Vitae
Paul S. Jellinger, M.D., M.A.C.E.
Page 2

POST-GRADUATE TRAINING:

Fellowship - Endocrinology (N.I.H. Fellow) The Mount Sinai Hospital New York City, N.Y. Fellowship - Endocrinology The Mount Sinai Hospital -- (Bronx V.A. Affiliation) New York, N.Y. Second Year Residency - Internal Medicine The Mount Sinai Hospital New York City, N.Y. First Year Residency - Internal Medicine Beth Israel Hospital New York City, N.Y. Internship - Straight Medicine Beth Israel Hospital New York City, N.Y.
SPECIALTY CERTIFICATION & LICENSURE:

1. American Board of Internal Medicine Sub-Specialty Board in Endocrinology & Metabolism Certified, October 1975 2. American Board of Internal Medicine Certified, June 1972 3. State of Florida License #22389 Issued June, 1974 4. New York State License #106101 Issued June, 1970 5. Diplomate, National Board of Medical Examiners - 1970
ACADEMIC APPOINTMENTS:
Curriculum Vitae
Paul S. Jellinger, M.D., M.A.C.E.
Page 3

Voluntary Faculty University of Miami School of Medicine Miami, Florida Department of Medicine (Endocrinology) University of Miami School of Medicine Department of Medicine (Endocrinology) University of Miami School of Medicine Miami, Department of Medicine (Endocrinology) University of Miami School of Medicine Miami, Director, Endocrine & Diabetes Clinic Jackson Memorial Hospital University of Miami School of Medicine Miami, Consulting Physician in Medicine (Endocrinology) Department of Medicine (Endocrinology) University of Miami School of Medicine Miami, Department of Medicine The Mt. Sinai School of Medicine New York City, N.Y.

HOSPITAL APPOINTMENTS:

Curriculum Vitae
Paul S. Jellinger, M.D., M.A.C.E.
Page 4

Memorial Regional Hospital -- Hollywood, FL Memorial Regional Hospital—Hollywood, FL Hollywood Medical Center—Hollywood, FL Jackson Memorial Hospital University of Miami School of Medicine—Miami, FL Director, Endocrine & Diabetes Clinic Jackson Memorial Hospital University of Miami School of Medicine—Miami, FL
PUBLICATIONS:

ACE/AACE DIABETES ROADMAPS TO ACHIEVE GLYCEMIC GOALS: CO-CHAIRMAN, ACE/AACE ROADMAP TASK FORCE Endocrine Practice, 2007, Vol. 13, No.3 May/June 2007, p.260- 268. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS (AACE) DIABETES MELLITUS CLINICAL PRACTICE GUIDELINES TASK FORCE Endocrine Practice, Vol. 13, (Suppl 1) May/June 2007 ACE/AACE CONSENSUS CONFERENCE ON THE IMPLEMENTATION OF OUTPATIENT MANAGEMENT OF DIABETES MELLITUS: CONSENSUS CONFERENCE RECOMMENDATIONS Endocrine Practice, Vol. 12, No. 1 Jan/Feb 2006, p. 6-12 AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS POSITION STATEMENT ON METABOLIC AND CARDIOVASCULAR CONSEQUENCES OF POLYCYSTIC OVARY SYNDROME Endocrine Practice, Vol. 11, No. 2 Mar/Apr 2005 p. 125-134 ACQUIRED HYPOTHYROIDISM AFTER SWITCHING FROM THYROID USP TO LEVOTHYROXINE Curriculum Vitae
Paul S. Jellinger, M.D., M.A.C.E.
Page 5

PUBLICATIONS (Continued):
AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON INSULIN RESISTANCE SYNDROME Endocrine Practice Vol. 9 No. 3, May/June 2003 p. 241-251 7. EMERGING CONCEPTS IN MANAGEMENT OF THE INSULIN RESISTANCE SYNDROME Endocrine Practice, Vol. 9, Supplement 2, Sept/Oct. 2003, p.105-112 AMERICAN COLLEGE OF ENDOCRINOLOGY CONSENSUS STATEMENT ON GUIDELINES FOR GLYCEMIC CONTROL Endocrine Practice, Vol. 8, Supplement 1, Jan/Feb 2002, p.5-11 RECOGNIZING CARDIOVASCULAR RISK IN PATIENTS WITH DIABETES The American Journal of Cardiology Continuing Education Series Monograph, 2002Editor POSTPRANDIAL HYPERGLYCEMIA AND CARDIOVASCULAR RISK The American Journal of Cardiology Continuing Education Series Monograph, 2002, p.11-15 A.A.C.E. MEDICAL GUIDELINES FOR THE TREATMENT OF DYSLIPIDEMIA IN THE PREVENTION OF ATHEROGENESIS Chairman, Task Force American Association of Clinical Endocrinologists, Endocrine Practice, Vol. 6, p. 162 –213, 2000 A.A.C.E. GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS, Task Force American Association of Clinical Endocrinologists, Revised, 2000 A.A.C.E. GUIDELINES FOR THE MANAGEMENT OF DIABETES MELLITUS, Task Force American Association of Clinical Endocrinologists, 1994 A.A.C.E. CLINICAL PRACTICE GUIDELINES FOR THE EVALUATION AND TREATMENT OF HYPERTHYROIDISM AND HYPOTHYROIDISM, Task Force American Association of Clinical Endocrinologists, 1994. PUBLICATIONS (Continued):
Curriculum Vitae
Paul S. Jellinger, M.D., M.A.C.E.
Page 6

LH RESPONSIVENESS IN SUBJECTS WITH SECONDARY AMENORRHEA: Clinical Research (abstra.), Vol. XXIII, No. 3, April, 1975 ORGANIZATIONS:

American Association of Clinical Endocrinologists
POSITIONS HELD:

Clinical Endocrinology News, Elsevier Publications January 2006 - American College of Endocrinology May 2004 – May 2005 American College of Endocrinology May 2003 – May 2004 American Association of Clinical Endocrinologists May 2000 - May 2001 American Association of Clinical Endocrinologist American Association of Clinical Endocrinologists May 1998 - May 1999 POSITIONS HELD (Continued):
7. Treasurer
Curriculum Vitae
Paul S. Jellinger, M.D., M.A.C.E.
Page 7

American Association of Clinical Endocrinologists May 1997 - May 1998 American Association of Clinical Endocrinologists May 1996 - May 1997 American Association of Clinical Endocrinologists San Diego, 1999 American Association of Clinical Endocrinologists May, 1996 - American Association of Clinical Endocrinologists Chicago, 1995 American Association of Clinical Endocrinologists 1998 - Program Chairman AACE Clinical Symposium Dyslipidemia, Diabetes & Obesity Montreal, August 1997 Program Chairman, American Diabetes Association Council on Endocrinology; Diabetes and Metabolism, "The DCCT: One Year Later." New Orleans Secretary, American Diabetes Association Council on Endocrinology; Diabetes and Metabolism Chairman, State Affiliate Organization Committee, American Association of Clinical Endocrinologists Chairman, Clinical MiniFellowship Program Committee American Association of Clinical Endocrinologists American Association of Clinical Endocrinologists
POSITIONS HELD (Continued):
American Association of Clinical Endocrinologists Curriculum Vitae
Paul S. Jellinger, M.D., M.A.C.E.
Page 8

Member, Committee on Clinical Practice and Technology American Association of Clinical Endocrinologists American Association of Clinical Endocrinologists Director, Endocrine & Diabetes Clinic Jackson Memorial Hospital University of Miami School of Medicine—Miami, FL 1975-1977
PROFESSIONAL SOCIETIES:

Master, American College of Endocrinology (M.A.C.E.) South Florida Endocrine Association-Founder, 1988 American Association of Clinical Endocrinologists American Heart Association Council on Arteriosclerosis Fellow, American College of Endocrinology (F.A.C.E.)
LECTURE, CONFERENCE & SEMINAR PRESENTATIONS:

Curriculum Vitae
Paul S. Jellinger, M.D., M.A.C.E.
Page 9

TOPICS
Thyroid Function Tests: An Update
Hypoglycemia
The Thyroid Nodule
Pituitary Disease: New Concepts
Hypercalcemia
Paget's Disease
Osteoporosis
Diabetes Mellitus - 1988 - An Update
Hyperlipidemia - NCME Video Tape-Moderator
Type II Diabetes, New Concepts-Moderator
Diabetes Complications and Control Trial:
A Landmark Study, November, 1993

HONORS:

1. President, American College of Endocrinology, May, 2004 – May 2005 2. Master, American College of Endocrinology, May, 2004 3. President, American Association of Clinical Endocrinologists, May, 2000- 4. Best Doctors in the United States, 2003-2004, as chosen by peers. 5. Best Doctors in the United States, 2001-2002, as chosen by peers. 6. Best Doctors in the United States, 2000, as chosen by peers 7. Best Doctors in Florida, 2000, as chosen by peers. 8. Best Doctors in the Southeast United States, 1999, as chosen by peers. 9. Best Doctors in South Florida, 1998, 2000, as chosen by peers. 10. Fellow, American College of Endocrinology, First Convocation and Assembly, May, 1994.
LOCAL REGIONAL & NATIONAL PRESENTATIONS:

1.
Juvenile Diabetes Research Foundation, Miami, FL 1975 Curriculum Vitae
Paul S. Jellinger, M.D., M.A.C.E.
Page 10

2.
Nursing Education, Memorial Regional Hospital—Hollywood, FL 1975-1979, Clinical Radioassay Society, Annual Meeting, Panel Moderator, 1980 Florida Osteopathic Medical Association, Annual Meeting, March 1990 American Society of Medical Technologists, Annual Meeting, Florida Division, 1981 Topic: Pituitary Disease: New Concepts & Testing Symposium, Memorial Regional Hospital—Hollywood, FL Topic: The Dynamics of Calcium Metabolism with Drs. L. Deftos and A. Florida Endocrine Society, Program Chairman & Moderator, May 1981 University of Miami, Sponsored Course in Endocrinology for the Diabetes Mellitus, Type II - New Concepts Roerig Speaker's Board, Pembroke Pines Hospital, March 1989 The Significance of HDL Cholesterol in the Hyperlipidemic State Parke Davis Speaker's Bureau, North Broward Regional Hospital, Hyperlipidemia 1990: An Update - The Role of HDL Cholesterol Parke Davis Speaker's Bureau, West Palm Beach, FL June 1990 Update on Hyperlipidemia - 1990 - The Role of HDL Cholesterol Parke Davis Speaker's Bureau, Jacksonville, FL April 1990 Lecturer in Endocrinology, annually, (Second Year Medical Students) Southeastern University of Health Sciences, N. Miami Beach, FL July 1990 The Significance of HDL Cholesterol in the Hyperlipidemic State Parke Davis Speaker's Bureau, Orlando, FL February 1991 Comparative Pharmacology of Agents Affecting Hypercholesterolemia Merck, Sharp & Dohme Speaker's Bureau, Orlando, FL May 29, 1991 Comparative Pharmacology of Agents Affecting Hypercholesterolemia Merck, Sharp & Dohme Speaker's Bureau, Ft Lauderdale, FL March 1992 Merck, Sharp & Dohme Speaker's Bureau, Ft Lauderdale, FL Nov. 1992 Florida Endocrine Society Annual Meeting 1976 - present
LOCAL, REGIONAL & NATIONAL PRESENTATIONS (Continued):
19.
Diabetic Neuropathy: Clinical Considerations American Association of Clinical Endocrinologists, Annual Meeting San Francisco, CA April, 1993 - Workshop Leader Diabetes Complications and Control Trial Curriculum Vitae
Paul S. Jellinger, M.D., M.A.C.E.
Page 11

Memorial Regional Hospital—Hollywood, FL November 1993 Diabetes Complications and Control Trial - A Landmark Study Pratt Pharmaceutical Speaker's Bureau, Hollywood, FL February 1994 Advanced Insulin Infusion Pump Symposium MiniMed Corporation, Ft Lauderdale, FL March 5th & 6th, 1994 Symposium Moderator & Workshop Leader Dyslipidemia: When to Treat, Who to Treat & How to Treat American Association of Clinical Endocrinologists, Annual Meeting New Orleans, Louisiana, April 1994, Workshop Moderator and Discussant Diabetes Complications and Control Trial: One Year Later Council on Endocrinology, Diabetes and Metabolism, American Diabetes Association Annual Meeting, Program Chairman and Moderator Hyperlipidemia: Treatment and Regression Merck, Sharp & Dohme Speaker's Bureau, Ft Lauderdale, FL June 1994 Diabetes Complications and Control Trial Results; Implications for Patients with Type II Diabetes, Sponsored by Novo Nordisk and Boehringer Mannheim Corp Holy Cross Hospital, Department of Medicine, Ft Lauderdale, FL July 1994 27. Atherosclerosis for the Endocrinologist: Lipids, Diabetes and Vascular Medicine American Association of Clinical Endocrinologists Regional Symposium Program Chairman and Discussant, Palm Beach, FL December 1994 A Practical Approach to the Treatment of Diabetic Neuropathy American Association of Clinical Endocrinologists Regional Symposium Method of Implementing Diabetes Intensive Self-Management in NIDDM American Association of Clinical Endocrinologists Regional Symposium, Keystone, CO January 1995 American Association of Clinical Endocrinologists, Annual Meeting, Workshop American Association of Clinical Endocrinologists, Annual Meeting Moderator & Discussant, Chicago, IL April 1995 NIDDM: Newer Concepts in Diabetic Management 92nd Annual Florida Osteopathic Medical Convention Doral Ocean Beach Resort, Miami Beach, FL March 1995 New Developments in the Treatment of Type II Diabetes Mellitus Department of Internal Medicine, North Broward Medical Center LOCAL, REGIONAL & NATIONAL PRESENTATIONS (Continued):
34.
New Concepts in Treatment of Type II Diabetes American Association of Diabetes Educators, South Florida Chapter Holy Cross Hospital, Ft Lauderdale, FL April 11, 1995 Lipid Disorders and Cardiovascular Disease in Women Cleveland Clinic Symposium: Women's Health Issues, Ft Lauderdale, FL June 1995 New Developments in the Treatment of Type II Diabetes Curriculum Vitae
Paul S. Jellinger, M.D., M.A.C.E.
Page 12

Memorial Regional/Pembroke Pines Hospital Medical Staff, Pembroke Pines, FL June 1995. New Developments in the Treatment of Type II Diabetes Coral Springs Hospital, Department of Internal Medicine/FP Case Studies in Intensive Self Management of Diabetes: Risk Factor AACE Symposium -- Keystone, CO January 1996 AACE Annual Meeting -- Seattle, WA May 1996 AACE Annual Meeting -- Seattle, WA May 1996

PREVIOUS RESEARCH PROJECTS:

1.
An Open Label Study of Fluvastatin in the Treatment of Patients with Hypercholesterolemia In Clinical Practice Settings Sandoz Pharmaceuticals -- Principal Investigator A Randomized, Multicenter Long-Term Follow-up Trial in Patients with Diabetic Foot Ulcers Telios Pharmaceuticals Inc. -- Co-Investigator Efficacy and Safety of Domperidone in Patients with Diabetic Gastroparesis Janssen Research -- Principal Investigator Treatment of Infected Diabetic Foot Ulcers Magainin Pharmaceuticals, Inc. -- Co-Investigator An Insulin Sensitizer in the treatment of NIDDM Patients Requiring Insulin, Phase I Parke-Davis Pharmaceutical Research -- Principal Investigator Bayer Pharmaceuticals -- Co-Investigator International Pharmaceutical Research -- Sub-Investigator Novo Nordisk Pharmaceuticals -- Principal Investigator PREVIOUS RESEARCH PROJECTS (Continued):
10.
Intravitreal injection of Hyaluronidase in Vitreal Hemorrhage Advanced Corneal Systems, Inc. -- Sub-Investigator Type II DM with Renal Impairment using Voglibose Takeda America, Inc. -- Sub-Investigator Open-Label Pramlintide in the Treatment in Type I DM Amylin Pharmaceuticals -- Principal Investigator Postmenopausal Women with Established Osteoporosis-Related Vertebral Curriculum Vitae
Paul S. Jellinger, M.D., M.A.C.E.
Page 13

Proctor & Gamble -- Principal Investigator Topical Nitroglycerin Cream for the Treatment of Erectile Dysfunction International Medcial Innovations, Inc. -- Sub-Investigator A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 9 Week Study of Omapatrilat in the Treatment of Mild to Moderate Hypertension Bristol-Myers Squibb -- Sub-Investigator A Randomized, Placebo-Controlled, Parallel-Group Study of CS-866 with Long-Term Safety Evaluation in Patients with Essential Hypertension Evaluating Metformin HCl Vs. Glyburide in Subjects With Type II Diabetes Mellitus Controlled On Sulfonylurea Monotherapy Bristol-Myers Squibb -- Principal Investigator An Open-Label, Community-Based Clinical Practice Study of Niaspan in Patients with Hyperlipidemia A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Prospectively Evaluate the Post-Prandial Glucose Excursion, the Daytime Glucose and Insulin Profiles, Safety, and Tolerability of a Fixed Dose of SDZ DJN 608, A Forced Titrated Dose of Glyburide, and Placebo in Subjects with NIDDM on Diet Alone Novartis Pharmaceuticals -- Sub-Investigator A Comparison of Echocardiographic Findings in Patients Treated with Redux Interneuron Pharmaceuticals, Inc.—Sub-Investigator TRICOR U.S. Multicenter Physician Experience Trial Abbott Laboratories Inc.—Principal Investigator Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Effects of Pramlintide on Glycemic Control as Determined by Glycated Hemoglobin in Patients with Type II Diabetes Mellitus Amylin Pharmaceuticals -- Sub-Investigator Open-Label Long-Term Study of the Antihypertensive Activity and Safety of Omapatrilat, a Dual Metalloprotease Inhibitor, in the Treatment of Hypertension Bristol-Myers Squibb -- Sub-Investigator Reach-Rezulin Achieves Glycemic Control; A Multicenter, 24-week, Open-Label, Dose-Escalation Trial of Rezulin in Combination with Insulin or Sulfonylurea in Type II Diabetes Mellitus Patients PREVIOUS RESEARCH PROJECTS (Continued):
25.
Safety and Efficacy of Fixed Combination Metformin/Glyburide Products as First Line Therapy in Patients with Type II Diabetes Mellitus who Have Inadequate Bristol-Myers Squibb -- Principal Investigator A Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Effects of Pramlintide on Glycemic Control as Determined by Glycated Hemoglobin in Patients with Type I Diabetes Mellitus Amylin Pharmaceuticals -- Sub-Investigator Curriculum Vitae
Paul S. Jellinger, M.D., M.A.C.E.
Page 14

27
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 18 Month Study to Assess the Safety and Efficacy of Meridia 20 mg Knoll Pharmaceuticals -- Co-Investigator A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of the Efficacy and Safety of Metformin Hydrochloride for the Treatment of Adolescents with Type 2 Diabetes Mellitus Bristol-Myers Squibb -- Sub-Investigator Efficacy and Safety of Inhaled Human Insulin Compared to Subcutaneous Human Insulin in an Intensive Insulin Regimen for Subjects with Type 1 DM Efficacy and Safety of Inhaled Human Insulin Therapy in Subjects with Type 2 DM Not Well-Controlled with Combination Oral Agents Double- Blind, Placebo- Controlled, Four-Week Study of the Safety and Efficacy of CP-386,296 in Subjects with Type 2 DM Glipizide GITZ Study in Usual Care Setting The Effect of PNU-182716 on HbA1c Levels in Type 2 Diabetic Patients, a Double-Blind, Placebo-Controlled, Randomized, Multicenter Dose-Finding Pharmacia & UpJohn – Sun-Investigator A Randomized, Double-Blind, Parallel- Group, Pilot Study of 3 Months Treatment with Oral GI262570 7.5 mg Once Daily, Pioglitazone 45 mg Once Daily, and Rosiglitazone 4 mg Twice Daily in Subjects with Type 2 DM Glaxo Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Noninsulin Dependent Diabetes Efficacy and Safety of Inhaled Human Insulin Therapy in Subjects with Type 2 Diabetes Mellitus not Optimally Controlled with Diet and Exercise Insulin Lispro Low Mixture Plus Metformin Compared to NPH Insulin Plus Metformin in Subjects with Type 2 DM Eli Lilly and Company – Sub-Investigator
CURRENT RESEARCH PROJECTS :
1.
A Triple-Blind, Parallel Study to Investigate the Effect of Losartan versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients The Hypopituitary Control and Complications Study with Humatrope Eli Lilly and Company -- Sub-Investigator Curriculum Vitae
Paul S. Jellinger, M.D., M.A.C.E.
Page 15

3.
Long Term Safety of Inhaled Insulin in Subjects with Type 1 or Type 2 DM Double-Blind, Randomized Study of the Safety and Efficacy of a Combination of Insulin and 30 mg of Actos vs. a Combination of Insulin and 45 mg of Actos in the Treatment Type 2 DM Takeda America -- Sub- Investigator A Randomized, Double-Blind, Parallel- Group, Placebo-Controlled Clinical Evaluation of GI262570 Sodium Tablets as a Monotherapy for 26 weeks in Subjects with Type 2 DM Glaxo A Randomized, Double-Blind, Parallel- Group, Clinical Evaluation GI262570 Sodium Tablets in Combination with Metformin for 26 weeks in Subjects with Type 2 DM Glaxo A Double-Blind, Randomized Comparison Study of the Safety and Efficacy of the Addition of Pioglitazone or Placebo in Reducing or Eliminating Insulin Requirement in Subjects Controlled on Insulin and Metformin Who Have Previously Failed Combination Oral Therapy Takeda Pharmaceuticals America—Sub-Investigator A Double-Blind, Randomized Comparison Study of the Long Term (2 yr) Safety and Efficacy of Pioglitazone or Glyburide in Subjects with Type 2 DM Naïve to Pharmacologic Therapy Takeda Pharmaceuticals America—Sub-Investigator Randomized, Multicenter, Double-Blind, Placebo-Controlled trial with Two Parallel Groups to Measure the Efficacy of 12 Weeks Treatment with 120 mg of Nateglinide vs Placebo in Treatment of Naïve Older Seniors with Type 2 DM Novartis Pharmaceuticals -- Sub-Investigator Multicenter, Randomized, Double-Blind Trial Comparing the Safety and Efficacy of Metformin/Glyburide to Pioglitazone in Patients with Type 2 DM Bristol-Myers Squibb -- Sub-Investigator Double-Blind Randomized Study to Evaluate the Effects of Fixed Combination Metformin/Glipizide in Patients with Type 2 DM Bristol-Myers Squibb – Sub-Investigator CURRENT RESEARCH PROJECTS (Continued):
12.
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effect on Glucose Control of AC2993 in Subjects with Type 2 DM Amylin Pharmaceuticals -- Sub-Investigator 18 Month, Double-Blind Phase 3 Trial with a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone in Women with Postmenopausal Osteoporosis NPS Allelix Corporation – Sub-Investigator Randomized, Open Label, Crossover Trial in Insulin Requiring Diabetic Patients, Comparing the Injections with BiaSp 30/MS216 Disposable Pen Device and Injections with BiaSp 30/vial and Syringe Curriculum Vitae
Paul S. Jellinger, M.D., M.A.C.E.
Page 16

Novo Nordisk Pharmaceuticals, Inc. – Sub-Investigator NNC61-0029 in Type 2 DM Hypertriglyceridemic Patients: Double-Blind, Parallel, Placebo-Controlled with an Open Pioglitazone Arm Novo Nordisk Pharmaceuticals, Inc. – Sub-Investigator Randomized, Double-Blind, Parallel-Group, Dose-Ranging Study to Assess the Efficacy and Safety of GI262570 Administered as a Daily Dose in Subjects with Type 2 DM Glaxo Wellcome, Inc. – Sub-Investigator Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Treatment with Simavastatin in TZD Treated Type 2 DM Patients Merck & Co., Inc. – Sub-Investigator Efficacy, Dose-Ranging and Safety for RWJ-241947 in Type 2 DM Patients Inadequately Controlled on Diet, Metformin, or Sulfonylurea: A Phase 2b Trial

Source: http://www.insulinresistance.us/bio/JellingerPaul.pdf